Background. Beta-trace protein (BTP) is a low-molecularweight glycoprotein, which may serve as an endogenous biomarker of kidney function and cardiovascular risk. Methods. We examined cardiovascular and all-cause mortality according to BTP concentrations in 2962 individuals referred for coronary angiography from the Ludwigshafen Risk and Cardiovascular Health study and in 907 patients with Type 2 diabetes mellitus undergoing haemodialysis from the German Diabetes and Dialysis (4D) study. Results. Haemodialysis patients had considerably higher median (interquartile range) BTP concentrations [6.00 (4.49-7.96) mg/L] and experienced a 4-fold increased mortality rate compared with coronary angiography patients ) mg/L]. After adjustment for age, sex, cardiovascular risk factors and creatinine, 4D patients in the highest quartile (>7.96 mg/ L) had a 1.6-fold increased rate of all-cause mortality [hazard ratio (HR) 1.62, 95% confidence interval (CI) 1.19-2.20] compared with the lowest quartile (<4.49 mg/L) (P ¼ 0.002) In patients undergoing coronary angiography, the adjusted HRs (95% CI) for all-cause and cardiovascular mortality were 1.23 (1.0-1.51) and 1.27 (0.99-1.63) in the highest (>0.67 mg/L) compared with the lowest (<0.44 mg/L) quartile (P ¼ 0.043 and 0.062). In both cohorts, the BTP/creatinine ratio was a stronger predictor of allcause and cardiovascular mortality compared with BTP. Conclusion. BTP was associated with all-cause mortality independently of renal function in haemodialysis patients. The BTP/creatinine ratio was more predictive for all-cause and cardiovascular mortality in haemodialysis patients and individuals referred for angiography compared with BTP as single marker.
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I N T R O D U C T I O N
Beta-trace protein (BTP) is a low-molecular-weight (23-29 kilodalton) monomeric glycoprotein of the lipocalin protein family [1] . Recently, a genome-wide study identified the gene encoding BTP in Europeans and African-Americans [2] .
Two main isoforms of BTP can be distinguished. The smaller 'brain' type isoform with truncated oligosaccharide side chains predominates in the cerebrospinal fluid (CSF) and is rapidly cleared through the liver, whereas the 'plasma' isoform with full-length sialylated oligosaccharide chains mainly occurs in the plasma and urine and is cleared through the kidney [3, 4] . The functional significance and relative concentrations of these different isoforms of BTP in healthy and sick individuals are not fully known yet [4] .
As BTP represents $10% of the total CSF proteins [5] , this biomarker has traditionally been used to detect CSF leakage [5, 6] . However, the messenger RNA of BTP has been detected in many human tissues (e.g. central nervous system, myocardial cells, atrial endocardial cells, fibrous plaques of atherosclerotic coronary arteries, male genital organs and melanocytes) [4, 7, 8] . This suggests that BTP may have many extracranial physiological roles in the human body.
In recent years, BTP has been described as a promising novel endogenous biomarker of glomerular filtration rate (GFR) in chronic kidney disease (CKD) [6, 8, 9] . In 1999, Priem et al. were the first to report that the BTP serum concentration was a new GFR marker in the creatinine-blind range in patients with diabetes mellitus [6, 10] . It is well known that reduced GFR is associated with a high prevalence of cardiovascular disease (CVD), cardiovascular mortality and hospitalization [11, 12] . Beyond its role to estimate kidney function, BTP has been proposed as a novel biomarker for cardiovascular risk [8] .
The gap of knowledge that this study fills is the investigation of BTP as a possible predictor of mortality independently of kidney function. Therefore, this study was conducted to investigate the value of BTP and the ratio of BTP/creatinine for predicting all-cause and cardiovascular mortality in 907 individuals with Type 2 diabetes mellitus, who underwent maintenance haemodialysis [German Diabetes and Dialysis (4D) study], and also in 2962 patients, who were referred for coronary angiography [Ludwigshafen Risk and Cardiovasular Health (LURIC) study].
M A T E R I A L S A N D M E T H O D S

Study design and participants
The LURIC study is a prospective cohort study designed to investigate genetic and serum biomarkers for CVD. A detailed description of the baseline examination has been published previously [13] . In total, 3316 individuals referred to coronary angiography were included between 1997 and 2000. The inclusion criteria were Caucasian individuals of German ancestry. The reasons of referral for coronary angiography were acute coronary syndrome (ACS) or scheduled selective coronary angiography in a stable clinical condition. The exclusion criteria were individuals with any acute illness other than ACS (i.e. other acute CVD or acute non-cardiac disease such as infection or recent surgery), patients with chronic non-cardiac diseases or with a history of malignancy within the past 5 years. The mean follow-up for all-cause and cardiovascular mortality was 10 years. BTP serum concentrations were available in 2962 patients (89.3% of the entire study cohort).
The 4D study is a prospective, double-blind, randomized, multicentre trial investigating if atorvastatin decreases the rate of cardiovascular mortality and nonfatal myocardial infarction in individuals with Type 2 diabetes undergoing haemodialysis. All in all, 1255 patients aged between 18 and 80 years, and treated by haemodialysis <2 years, were included [14] . Between 1998 and 2002, patients were recruited at 178 dialysis centres in Germany. The mean follow-up period, during which clinical information and adverse effects were collected, was 4 years. For BTP measurements serum was available from 907 patients (72.3% of the entire study cohort).
In both study cohorts physical examination (i.e. weight, height and blood pressure), standardized questionnaire (i.e. smoking status, alcohol use and medication), laboratory procedures (i.e. sample collection and storage of serum aliquots), and statistical analyses were performed in the same way. The studies were carried out in accordance with the Declaration of Helsinki and were approved by the medical ethics committees, and all participants gave their written informed consent.
Laboratory procedures
Venous blood sampling was performed in the fasting state in the morning (between 8.00 and 10.00 a.m.) before coronary angiography in LURIC patients and before the start of dialysis sessions in 4D patients. Blood was collected (9 mL S-Monovette tubes, Sarstedt AG, Nümbrecht, Germany) and was allowed to clot for 40 min followed by centrifugation (15 min; 2000g; 4 C). Serum was aliquoted, snap-frozen in liquid nitrogen and longterm stored at À80 C until analysis followed a single freezethaw cycle (15 years after blood collection).
In both studies, BTP levels were measured with the latexenhanced N Latex BTP Assay on the BN TM II System (Siemens Healthcare GmbH, Vienna, Austria). This assay is based on a latex-particle-enhanced immunonephelometric method. The within-day coefficients of variation (CVs) were 0.8% (1.02 mg/L) and 1.7% (1.83 mg/L) and the between-day CVs were 3.5% (1.02 mg/L) and 3.1% (1.83 mg/L), respectively. Serum creatinine was determined by liquid chromatography tandem-mass spectrometry (LC-MS/MS) as described in detail elsewhere [15] . The within-day and between-day CVs for creatinine were 4.5% (58.9 mmol/L) and 2.9% (477.3 mmol/L); and 9.6% (53.2 mmol/L) and 7.5% (504 mmol/L), respectively. The estimated GFR (eGFR) was calculated with the CKD Epidemiology Collaboration (CKD-EPI) equation [16] .
Haemoglobin, glycohaemoglobin A1c (HbA1c), low-density lipoprotein (LDL)-and high-density lipoprotein (HDL)-cholesterol, albumin and antithrombin III (AT III) were measured by standard laboratory procedures as described previously [13] . The high-sensitivity C-reactive protein (hs-CRP) was determined by immunonephelometry [N Latex CRP mono (Dade Behring, Marburg, Germany)]. The N-terminal pro-B-type natriuretic peptide (NT-proBNP) was measured with an electrochemoluminescence immunoassay (Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Normally distributed continuous variables were presented as means 6 standard deviation, and not normally distributed variables as medians with interquartile ranges (Q1-Q3). Categorical variables were expressed as percentages.
To assess the association of BTP serum levels with cardiovascular and all-cause mortality in the LURIC and in the 4D studies, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard models according to the quartiles of BTP (Model 1, Table 2 ). First, we performed multivariable adjustments for confounders including age and sex (Model 2, Table 2 ). Second, we conducted multivariable adjustments for well-established risk factors of CVD [i.e. smoking status, LDL-and HDL-cholesterol, hypertension and diabetes mellitus (Model 3, Table 2 )]. In the statistical Model 4 (Table 2), we additionally adjusted for the kidney function (i.e. creatinine) to see whether the predictive value of BTP was related to kidney function. We also fitted statistical models according to the quartiles of the BTP/creatinine ratio (Model 1, Table 3 ), because creatinine is primarily excreted unchanged by the kidneys, whereas BTP is also enzymatically metabolized via the liver. Multivariable adjustments were calculated for the same confounders (Model 2, Table 3 : age and sex; Model 3, Table 3 : smoking status, LDL-and HDL-cholesterol, hypertension and diabetes mellitus) as in the models for BTP. In the 4D cohort, putative interactions of randomization with BTP or the BTP/creatinine ratio were also considered.
In the LURIC cohort, differences of liver parameters between quartiles of BTP and the BTP/creatinine ratio were analyzed by analysis of variance. Finally, we investigated and compared the absolute incidence rates of mortality (deaths per 1000 person-years) in both cohorts according to the BTP serum concentrations. All statistical tests were two-sided, and a Pvalue <0.05 was considered statistically significant. The analyses were performed using SPSS 20.0 statistical software (SPSS Inc., Chicago, IL, USA).
R E S U L T S
Study populations and BTP status
The clinical and laboratory characteristics of the study participants of the LURIC and 4D studies are shown in Table 1 . The average age was 62.8 6 10.6 years in the LURIC study, and 68.7% of participants were men. In the 4D study, the mean age was 66.8 6 8.3 years, and 54.0% of the participants were male. In the LURIC and in the 4D cohort BTP measurements were not available in 354/3316 (10.7%) and in 348/1255 (27.7%) individuals, respectively. The baseline characteristics of these patients are presented in the Supplementary data, Table S1 .
In the LURIC and 4D cohorts the median BTP serum levels (interquartile ranges) were 0.55 (0.44-0.67) and 6.00 (4.49-7.96) mg/L, respectively. BTP serum concentrations increased with decreasing renal function. The median BTP serum levels (interquartile ranges) in patients with normal (eGFR !90 mL/ min/1.73 m In the 4D cohort, 462 (50.9%) and 445 (49.1%) out of 907 individuals were in the active treatment (atorvastatin) and in the placebo group, respectively. The median BTP serum level in the active treatment group was 6.07 (4.53-7.81) mg/L compared with the placebo group with 6.00 (4.41-8.30) mg/L (P ¼ 0.367). Atorvastatin treatment had no significant influence on the HRs of all-cause (P ¼ 0.843) and cardiovascular mortality (P ¼ 0.202), respectively.
Association of BTP and the BTP/creatinine ratio with mortality in individuals undergoing coronary angiography (LURIC study)
After a mean follow-up of 10 years, 809 patients died, including 550 deaths due to cardiovascular causes. By Cox regression analyses, patients in the highest BTP quartile (>0.67 mg/L) had , outliers >1.5 and <3 interquartile range (IQR); *, outliers >3 IQR. a >2-fold higher rate of death due to any cause (HR 2.27, 95% CI 1.89-2.72) and cardiovascular death (HR 2.37, 95% CI 1.89-2.97) than patients in the lowest quartile (<0.44 mg/L) (Model 1). The associations remained significant, but were decreased after adjustments for age and sex (HR for death due to any cause 1 Table 2 ).
The associations between the BTP/creatinine ratio and mortality in LURIC patients are shown in Table 3 . Patients in the highest quartile of BTP/creatinine ratio (>0.73) had a 2-fold higher rate of death due to any cause (HR 1.98, 95% CI 1.98-2.37) and a 1.8-fold increased rate of cardiovascular death (HR 1.80, 95% CI 1.44-2.27) compared with patients in the lowest quartile (<0.73). After multivariable adjustments the associations remained mostly significant.
To assess the impact of liver function on BTP concentrations we calculated differences of AT III and albumin between BTP quartiles. Higher BTP levels were significantly associated with lower AT III concentrations. The additional adjustment for creatinine increased the effects so that both liver parameters were inversely associated with BTP serum levels in a significant way (Supplementary data, Table S2 ).
Association of BTP and the BTP/creatinine ratio with mortality in haemodialysis patients (4D study)
During a mean follow-up period of 4 years, 456 patients died, of whom 205 individuals died of cardiovascular causes. Compared with subjects in the LURIC study, individuals in the 4D study showed an $4-fold higher risk of death (incidence rate per 1000 person-years), which was well reflected by higher BTP concentrations (Figure 2) .
By Cox regression analyses, no predictive effects of BTP were found in all statistical models, which were unadjusted for the kidney function (Models 1-3, Table 2 ). However, following additional adjustment for creatinine revealed a strong association between BTP and all-cause mortality (Model 4, Table 2 ). Individuals in the highest BTP quartile (>7.96 mg/L) had a 1.6-fold increased rate of death due to any cause (HR 1.62, 95% CI 1.19-2.20) compared with patients in the lowest BTP quartile (<4.50 mg/L), respectively.
When we calculated the BTP/creatinine ratio, we found even stronger associations with all-cause and cardiovascular mortality. Patients in the highest quartile of the BTP/creatinine ratio (>1.12) had a 1.9-fold higher rate of death due to any cause (HR 1.85, 95% CI 1.43-2.40) and a 1.7-fold increased rate Table 3 . HRs (95% CIs) for all-cause and cardiovascular mortality according to quartiles of the ratio of serum BTP and serum creatinine concentrations at baseline in study participants in the LURIC and 4D studies Model 2: adjustments were made for age and sex. c Model 3: further adjustments additional to Model 2 were made for potential confounders: smoking status, LDL-and HDL-cholesterol, hypertension and diabetes.
Bold P-value of <0.05 was considered statistically significant. (Table 3 ).
In the 4D study 454/907 (50%) patients were on haemodialysis for >6 months. In those on haemodialysis >6 months, individuals in the highest BTP quartile (>9.25 mg/L) were in tendency or significantly associated with all-cause and cardiovascular mortality compared with patients in the lowest quartile (<4.76 mg/L). Those 453/907 (50%) individuals on haemodialysis <6 months showed no significant associations of BTP with mortality or cardiovascular mortality (Supplementary data, Table S3 ).
The predictive values for mortality of creatinine alone in comparison with BTP alone and the BTP/creatinine ratio in haemodialysis patients are given in the Supplementary data, Table S4 . Creatinine alone was not a predictive marker, whereas BTP alone was associated with all-cause mortality, and the BTP/creatinine ratio was predictive for all-cause and cardiovascular mortality.
D I S C U S S I O N
Herein we investigated the effect of BTP on cardiovascular outcomes and all-cause mortality in two large clinical cohorts, 2962 individuals referred for coronary angiography (LURIC study) and 907 patients with Type 2 diabetes mellitus undergoing haemodialysis (4D study). In patients undergoing coronary angiography the adjusted HRs (95% CI) for all-cause and cardiovascular mortality were 1.23 (1.01-1.51) and 1.27 (0.99-1.63) in individuals in the highest BTP quartile compared with the lowest quartile. In haemodialysis patients (4D study) BTP levels were significantly higher. Individuals in the highest BTP quartile showed a HR for all-cause mortality of 1.62 (1.19-2.20) compared with the lowest quartile independently of renal function.
In comparison, a previously published study by Shafi et al., in which 503 incident haemodialysis patients were recruited, reported a higher adjusted HR of 1.72 (95% CI 1.25-2.37) for all-cause mortality and also a strong association of serum BTP levels (HR 1.63, 95% CI 1.03-2.58) with cardiovascular mortality in the highest BTP tertile compared with the lowest tertile [17] . Differences between the study designs and participants may be potential reasons for the different HRs. In the 4D cohort we recruited 907 individuals with a mean age of 66.8 years. All of them had diabetes mellitus and the median time from onset of dialysis to blood collection was 8.3 (range: 6.9-10.4) months. In comparison, Shafi et al. studied 503 participants with a mean age of 58 years. They had renal failure due to diabetes mellitus in 50% only and the median time from dialysis initiation to blood sampling was 4.8 (range: 3.8-6.1) months [17] .
In contrast to Shafi et al. [17] , we calculated a Cox regression model (Model 4 in Table 2 ) with additional adjustment for creatinine and found BTP to be strongly associated with allcause mortality, whereas no associations could be found in all other statistical models for all-cause and cardiovascular mortality in haemodialysis patients in 4D. These data indicate a predictive value of BTP as single marker for mortality due to any cause of death irrespective of renal function. Moreover, compared with BTP alone the BTP/creatinine ratio was more predictive for allcause and cardiovascular mortality in haemodialysis patients. After the adjustment for potential confounders, patients in the highest quartile of BTP/creatinine ratio had a 80% higher rate of death due to any cause, and a 60% higher rate of cardiovascular death compared with patients in the lowest quartile.
These results are indicative of a relationship of BTP with mortality independent from creatinine. Creatinine alone was not a predictive marker of mortality, whereas BTP was associated with all-cause mortality in haemodialysis patients and the BTP/creatinine ratio increased the predictive value for all-cause and cardiovascular mortality. One possible explanation for BTP/creatinine ratio being the better predictor for outcome is that serum creatinine is produced by the nonenzymatic dehydration of muscle creatine and primarily excreted unchanged and without enzymatic metabolism by glomerular filtration in the kidneys [18] . It represents an important marker of renal function. In comparison, the metabolism of BTP is substantially different from creatinine because BTP uses also an enzymatically pathway via the liver. The nonsialylated glycoforms of BTP are rapidly eliminated by specific glycoprotein receptors of the liver, whereas the sialysed and bigger glycoforms of BTP are excreted via glomerular filtration [3, 4, 19] . Because of these different metabolic pathways between creatinine and BTP, we used the BTP/creatinine ratio to consider the predictive value of BTP independently from the kidney function.
We suggest that the hepatic metabolism may have an essential role in the BTP degradation, but prospective metabolic studies in humans are still lacking [19] . To assess the impact of liver function on BTP levels we investigated AT III and albumin across the BTP quartiles of the LURIC cohort. Individuals with higher BTP serum levels had lower liver function parameters. The additional adjustment of creatinine further increased these effects. These data raise the possibility that liver function affects BTP concentrations and that BTP reflects adverse prognosis in individuals undergoing haemodialysis due to impaired liver function. Follow-up studies are of course needed to fully investigate the hepatic metabolism of BTP in haemodialysis patients.
Interestingly, in 454/907 (50%) individuals of the 4D cohort, who were on hemodialysis for >6 months, the highest BTP quartiles were significantly associated with all-cause and cardiovascular mortality compared with those 4D patients who were on renal replacement therapy <6 months. Moreover, also in 190/907 (21%) individuals receiving diuretics no associations were found between BTP and all-cause or cardiovascular mortality (data not shown). This in turn indicates, that the serum BTP level seems to be a less predictive mortality parameter in patients with residual renal function (RRF). The RRF could also be responsible for the large variability of BTP levels found in haemodialysis patients here.
Beta-trace protein and mortality We investigated two separate large follow-up cohorts, in which the clinical examinations and the laboratory procedures were done in the same way. Our analysis shows that the BTP concentration directly indicates the CVD mortality risk, regardless of whether somebody participated in the 4D study or in the LURIC study, along the cardiorenal continuum (Figures 1  and 2 ). In our analyses, we divided the entire LURIC cohort into subgroups according to their eGFR (Figure 1 ). BTP levels increased with decreasing kidney function. The relationship between increasing BTP serum levels and the incidence rates of death (incidence rate per 1000 person-years) extended from the lowest concentrations in persons undergoing angiography to the highest concentrations in diabetic patients undergoing haemodialysis (Figure 2 ).
Since deaths from CVD are increasing worldwide, the identification of novel cardiovascular risk factors is essential with respect to further improving the diagnostic approach and therapeutic strategies of these patients [20, 21] . In the LURIC cohort BTP as a single marker was a predictor of all-cause and cardiovascular mortality. The BTP/creatinine ratio was even stronger associated with all-cause and cardiovascular mortality in individuals referred for angiography compared with BTP alone. Patients in the highest quartile of BTP/creatinine ratio had a 50% and 40% higher adjusted rate of death due to any and cardiovascular cause, respectively, compared with patients in the lowest quartile.
The strengths of this study are the uniform measurements of BTP with identical methods in two large clinical cohorts, the adequate sample size, and the broad range of kidney function, covering normal and impaired renal function, as well as endstage renal disease.
Nevertheless, some limitations of this study must be mentioned: serum aliquots of BTP were measured 15 years after blood collection. According to the instructions of the manufacturer a single freeze-thaw cycle has no effect on specimens, but there is no evidence from other sources of BTP preservation over this period of time. BTP serum levels were obtained at one single time point. Therefore, the intrapatient variability of BTP was not available. In both study cohorts data of BTP measurements were missing because of too little sample specimen. Further, in both study cohorts urine samples were not collected. This is why adjustments were not performed for albuminuria as a possible determinant of all-cause mortality. Finally, we had no information about the treatment with diet, oral medication or insulin in individuals with Type 2 diabetes mellitus in the 4D cohort. Similarly, the average dialysis Kt/V, the residual urine volume and the liver function parameter AT III were not available in individuals of the 4D study cohort.
In conclusion, in diabetic patients undergoing haemodialysis the serum level of BTP showed a strong association with all-cause mortality after adjustment for kidney function. The BTP/creatinine ratio was better predictive for allcause and cardiovascular mortality in haemodialysis patients as well as in individuals referred for angiography compared with BTP as single marker. In the care of patients with CKD, the BTP/creatinine ratio represents a more effective diagnostic tool to predict mortality independently of kidney function. To get better insight in the hepatic metabolism of BTP degradation, we suggest conducting further prospective studies including liver function parameters in haemodialysis patients.
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